- Home
- TACT vs VNRX Comparison
TACT vs VNRX Comparison
Compare TACT & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TACT | VNRX |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.1M | 40.8M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | TACT | VNRX |
|---|---|---|
| Price | $4.47 | $0.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $5.00 | $3.17 |
| AVG Volume (30 Days) | 49.1K | ★ 2.5M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,258,000.00 | $1,472,007.00 |
| Revenue This Year | $21.67 | $324.32 |
| Revenue Next Year | $7.63 | $247.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 8.27 | ★ 14.48 |
| 52 Week Low | $3.12 | $0.29 |
| 52 Week High | $5.70 | $0.94 |
Technical Indicators
Market Signals| Indicator | TACT | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.95 | 32.33 |
| Support Level | $4.30 | $0.29 |
| Resistance Level | $4.75 | $0.33 |
| Average True Range (ATR) | 0.25 | 0.03 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 64.71 | 7.66 |
Price Performance
Historical ComparisonAbout TACT TransAct Technologies Incorporated
Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.